ProACE inhibitors (ACEi) and Ang II receptor blockers (ARBs), both inducing the expression of ACE2, are thought to be beneficial in COVID-19. Experiments with double mutant Akita (murine model for human diabetes)/ACE2 KO mice revealed that the loss of ACE2 leads to impaired vascular function. This effect was observed only in double mutant mice, whereby neither Akita mice nor ACE2 KO mice alone demonstrate such changes. ContraComorbidity of obesity and T2D with severity of COVID-19 was observed in viral infections other than SARS-CoV/CoV-2 and thus is not ACE2 specific. Here, ACE2 is linked to COVID-19.